Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing
two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis
with a standard acquisition protocol (as outlined in the protocol) as well as CT chest. A CT
of the abdomen and pelvis may be performed if there are contraindications to MRI. Patients
will also undergo a restaging cystoscopy and biopsies/TURBT as outlined in the protocol.
Patients achieving a clinical complete response to treatment (defined in the protocol) will
proceed with "maintenance" single agent pembrolizumab followed by surveillance. All other
patients will proceed with standard of care local therapy as per their treating physicians
followed by "adjuvant" pembrolizumab.